U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry RACEMIC
Molecular Formula C12H24N2O4
Molecular Weight 260.33
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of CARISOPRODOL

SMILES

CCCC(C)(COC(N)=O)COC(=O)NC(C)C

InChI

InChIKey=OFZCIYFFPZCNJE-UHFFFAOYSA-N
InChI=1S/C12H24N2O4/c1-5-6-12(4,7-17-10(13)15)8-18-11(16)14-9(2)3/h9H,5-8H2,1-4H3,(H2,13,15)(H,14,16)

HIDE SMILES / InChI

Molecular Formula C12H24N2O4
Molecular Weight 260.33
Charge 0
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )

Description
Curator's Comment: description was created based on several sources, including: http://www.ncbi.nlm.nih.gov/pubmed/22318620, http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7c9184c0-7a2e-11df-8c8d-0002a5d5c51b

A centrally acting skeletal muscle relaxant whose mechanism of action is not completely understood but may be related to its sedative actions. Carisoprodol is indicated for the relief of discomfort associated with acute, painful musculoskeletal conditions in adults. Most common adverse reactions (incidence > 2%) are drowsiness, dizziness, and headache. Carisoprodol might be mixtured with Aspirin and Codeine Phosphate. Studies indicating increased risk of abuse or addiction led to withdrawal of the drug from the market in Norway and other EU countries in 2008.

Originator

Curator's Comment: Carisoprodol was developed in the 1950s by Dr. Frank M. Berger at Wallace laboratories on the basis of meprobamate.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
142.0 µM [EC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Palliative
SOMA

Approved Use

SOMA is indicated for the relief of discomfort associated with acute, painful musculoskeletal conditions in adults. SOMA should only be used for short periods (up to two or three weeks) because adequate evidence of effectiveness for more prolonged use has not been established and because acute, painful musculoskeletal conditions are generally of short duration

Launch Date

1959
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
13.3 μM
700 mg single, oral
dose: 700 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CARISOPRODOL serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
1.2 μg/mL
250 mg single, oral
dose: 250 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CARISOPRODOL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
1.8 μg/mL
350 mg single, oral
dose: 350 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CARISOPRODOL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
4.5 μg × h/mL
250 mg single, oral
dose: 250 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CARISOPRODOL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
7 μg × h/mL
350 mg single, oral
dose: 350 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CARISOPRODOL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
99 min
700 mg single, oral
dose: 700 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CARISOPRODOL serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
1.7 h
250 mg single, oral
dose: 250 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CARISOPRODOL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
2 h
350 mg single, oral
dose: 350 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CARISOPRODOL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
46%
700 mg single, oral
dose: 700 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CARISOPRODOL serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
Doses

Doses

DosePopulationAdverse events​
250 mg 3 times / day steady, oral
Recommended
Dose: 250 mg, 3 times / day
Route: oral
Route: steady
Dose: 250 mg, 3 times / day
Sources:
unhealthy, 41 years
Health Status: unhealthy
Age Group: 41 years
Sex: M+F
Sources:
Disc. AE: Dizziness, Headache...
AEs leading to
discontinuation/dose reduction:
Dizziness (0.5%)
Headache (0.5%)
Diarrhea (0.2%)
Stomach discomfort (0.2%)
Upper abdominal pain (0.2%)
Intervertebral disc protrusion (0.2%)
Pain in extremity (0.2%)
Abdominal distension (0.2%)
Sources:
350 mg 3 times / day steady, oral
Recommended
Dose: 350 mg, 3 times / day
Route: oral
Route: steady
Dose: 350 mg, 3 times / day
Sources:
unhealthy, 41 years
Health Status: unhealthy
Age Group: 41 years
Sex: M+F
Sources:
Disc. AE: Dizziness, Headache...
AEs leading to
discontinuation/dose reduction:
Dizziness (0.7%)
Headache (0.4%)
Stomach discomfort (0.7%)
Upper abdominal pain (0.7%)
Somnolence (0.7%)
Nausea (0.4%)
Rash (0.4%)
Nephrolithiasis (0.4%)
Intervertebral disc protrusion (0.4%)
Fatigue (0.4%)
Disorientation (0.4%)
Paraesthesia (0.4%)
Skin papilloma (0.4%)
Sources:
2100 mg 1 times / day steady, oral
Highest studied dose
Dose: 2100 mg, 1 times / day
Route: oral
Route: steady
Dose: 2100 mg, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: M
Sources:
AEs

AEs

AESignificanceDosePopulation
Abdominal distension 0.2%
Disc. AE
250 mg 3 times / day steady, oral
Recommended
Dose: 250 mg, 3 times / day
Route: oral
Route: steady
Dose: 250 mg, 3 times / day
Sources:
unhealthy, 41 years
Health Status: unhealthy
Age Group: 41 years
Sex: M+F
Sources:
Diarrhea 0.2%
Disc. AE
250 mg 3 times / day steady, oral
Recommended
Dose: 250 mg, 3 times / day
Route: oral
Route: steady
Dose: 250 mg, 3 times / day
Sources:
unhealthy, 41 years
Health Status: unhealthy
Age Group: 41 years
Sex: M+F
Sources:
Intervertebral disc protrusion 0.2%
Disc. AE
250 mg 3 times / day steady, oral
Recommended
Dose: 250 mg, 3 times / day
Route: oral
Route: steady
Dose: 250 mg, 3 times / day
Sources:
unhealthy, 41 years
Health Status: unhealthy
Age Group: 41 years
Sex: M+F
Sources:
Pain in extremity 0.2%
Disc. AE
250 mg 3 times / day steady, oral
Recommended
Dose: 250 mg, 3 times / day
Route: oral
Route: steady
Dose: 250 mg, 3 times / day
Sources:
unhealthy, 41 years
Health Status: unhealthy
Age Group: 41 years
Sex: M+F
Sources:
Stomach discomfort 0.2%
Disc. AE
250 mg 3 times / day steady, oral
Recommended
Dose: 250 mg, 3 times / day
Route: oral
Route: steady
Dose: 250 mg, 3 times / day
Sources:
unhealthy, 41 years
Health Status: unhealthy
Age Group: 41 years
Sex: M+F
Sources:
Upper abdominal pain 0.2%
Disc. AE
250 mg 3 times / day steady, oral
Recommended
Dose: 250 mg, 3 times / day
Route: oral
Route: steady
Dose: 250 mg, 3 times / day
Sources:
unhealthy, 41 years
Health Status: unhealthy
Age Group: 41 years
Sex: M+F
Sources:
Dizziness 0.5%
Disc. AE
250 mg 3 times / day steady, oral
Recommended
Dose: 250 mg, 3 times / day
Route: oral
Route: steady
Dose: 250 mg, 3 times / day
Sources:
unhealthy, 41 years
Health Status: unhealthy
Age Group: 41 years
Sex: M+F
Sources:
Headache 0.5%
Disc. AE
250 mg 3 times / day steady, oral
Recommended
Dose: 250 mg, 3 times / day
Route: oral
Route: steady
Dose: 250 mg, 3 times / day
Sources:
unhealthy, 41 years
Health Status: unhealthy
Age Group: 41 years
Sex: M+F
Sources:
Disorientation 0.4%
Disc. AE
350 mg 3 times / day steady, oral
Recommended
Dose: 350 mg, 3 times / day
Route: oral
Route: steady
Dose: 350 mg, 3 times / day
Sources:
unhealthy, 41 years
Health Status: unhealthy
Age Group: 41 years
Sex: M+F
Sources:
Fatigue 0.4%
Disc. AE
350 mg 3 times / day steady, oral
Recommended
Dose: 350 mg, 3 times / day
Route: oral
Route: steady
Dose: 350 mg, 3 times / day
Sources:
unhealthy, 41 years
Health Status: unhealthy
Age Group: 41 years
Sex: M+F
Sources:
Headache 0.4%
Disc. AE
350 mg 3 times / day steady, oral
Recommended
Dose: 350 mg, 3 times / day
Route: oral
Route: steady
Dose: 350 mg, 3 times / day
Sources:
unhealthy, 41 years
Health Status: unhealthy
Age Group: 41 years
Sex: M+F
Sources:
Intervertebral disc protrusion 0.4%
Disc. AE
350 mg 3 times / day steady, oral
Recommended
Dose: 350 mg, 3 times / day
Route: oral
Route: steady
Dose: 350 mg, 3 times / day
Sources:
unhealthy, 41 years
Health Status: unhealthy
Age Group: 41 years
Sex: M+F
Sources:
Nausea 0.4%
Disc. AE
350 mg 3 times / day steady, oral
Recommended
Dose: 350 mg, 3 times / day
Route: oral
Route: steady
Dose: 350 mg, 3 times / day
Sources:
unhealthy, 41 years
Health Status: unhealthy
Age Group: 41 years
Sex: M+F
Sources:
Nephrolithiasis 0.4%
Disc. AE
350 mg 3 times / day steady, oral
Recommended
Dose: 350 mg, 3 times / day
Route: oral
Route: steady
Dose: 350 mg, 3 times / day
Sources:
unhealthy, 41 years
Health Status: unhealthy
Age Group: 41 years
Sex: M+F
Sources:
Paraesthesia 0.4%
Disc. AE
350 mg 3 times / day steady, oral
Recommended
Dose: 350 mg, 3 times / day
Route: oral
Route: steady
Dose: 350 mg, 3 times / day
Sources:
unhealthy, 41 years
Health Status: unhealthy
Age Group: 41 years
Sex: M+F
Sources:
Rash 0.4%
Disc. AE
350 mg 3 times / day steady, oral
Recommended
Dose: 350 mg, 3 times / day
Route: oral
Route: steady
Dose: 350 mg, 3 times / day
Sources:
unhealthy, 41 years
Health Status: unhealthy
Age Group: 41 years
Sex: M+F
Sources:
Skin papilloma 0.4%
Disc. AE
350 mg 3 times / day steady, oral
Recommended
Dose: 350 mg, 3 times / day
Route: oral
Route: steady
Dose: 350 mg, 3 times / day
Sources:
unhealthy, 41 years
Health Status: unhealthy
Age Group: 41 years
Sex: M+F
Sources:
Dizziness 0.7%
Disc. AE
350 mg 3 times / day steady, oral
Recommended
Dose: 350 mg, 3 times / day
Route: oral
Route: steady
Dose: 350 mg, 3 times / day
Sources:
unhealthy, 41 years
Health Status: unhealthy
Age Group: 41 years
Sex: M+F
Sources:
Somnolence 0.7%
Disc. AE
350 mg 3 times / day steady, oral
Recommended
Dose: 350 mg, 3 times / day
Route: oral
Route: steady
Dose: 350 mg, 3 times / day
Sources:
unhealthy, 41 years
Health Status: unhealthy
Age Group: 41 years
Sex: M+F
Sources:
Stomach discomfort 0.7%
Disc. AE
350 mg 3 times / day steady, oral
Recommended
Dose: 350 mg, 3 times / day
Route: oral
Route: steady
Dose: 350 mg, 3 times / day
Sources:
unhealthy, 41 years
Health Status: unhealthy
Age Group: 41 years
Sex: M+F
Sources:
Upper abdominal pain 0.7%
Disc. AE
350 mg 3 times / day steady, oral
Recommended
Dose: 350 mg, 3 times / day
Route: oral
Route: steady
Dose: 350 mg, 3 times / day
Sources:
unhealthy, 41 years
Health Status: unhealthy
Age Group: 41 years
Sex: M+F
Sources:
Overview

Overview

OverviewOther

Other InhibitorOther SubstrateOther Inducer



Drug as perpetrator​Drug as victim
PubMed

PubMed

TitleDatePubMed
National All Schedules Prescription Electronic Reporting Act (NASPER): balancing substance abuse and medical necessity.
2002 Jul
A near-fatal overdose of carisoprodol (SOMA): case report.
2004
Comparative efficacy and safety of skeletal muscle relaxants for spasticity and musculoskeletal conditions: a systematic review.
2004 Aug
Prescription of nonsteroidal anti-inflammatory drugs and muscle relaxants for back pain in the United States.
2004 Dec 1
Impairment due to intake of carisoprodol.
2004 Jun 11
Identifying controlled substance patterns of utilization requiring evaluation using administrative claims data.
2004 Nov
Stimulant and relaxant drugs combined with stimulant and relaxant information: a study of active placebo.
2004 Nov
Recent trends of drug abuse and drug-associated deaths in Korea.
2004 Oct
Simultaneous determination of carisoprodol and meprobamate in human hair using solid-phase extraction and gas chromatography/mass spectrometry of the trimethylsilyl derivatives.
2005
The CYP2C19 genotype and the use of oral contraceptives influence the pharmacokinetics of carisoprodol in healthy human subjects.
2005 Aug
Human pharmaceuticals, hormones, and personal care product ingredients in runoff from agricultural fields irrigated with treated wastewater.
2005 Mar 9
Treatment of carisoprodol dependence: a case report.
2005 Sep
Simple pharmacological test battery to assess efficacy and side effect profile of centrally acting muscle relaxant drugs.
2005 Sep-Oct
Biology and therapy of fibromyalgia. New therapies in fibromyalgia.
2006
A one-step and sensitive GC-MS assay for meprobamate determination in emergency situations.
2006 Jun
Carisoprodol withdrawal induced delirium: A case study.
2007
Carisoprodol use and abuse in Norway: a pharmacoepidemiological study.
2007 Aug
Carisoprodol abuse in Mississippi.
2007 Dec
Drug screening of preserved oral fluid by liquid chromatography-tandem mass spectrometry.
2007 Feb
Do motor control genes contribute to interindividual variability in decreased movement in patients with pain?
2007 Jul 26
[Somadril recalled in Norway].
2007 May 17
Upper limb impairments associated with spasticity in neurological disorders.
2007 Nov 29
[Somadril will be recalled June 1, 2008].
2008 Apr 2-8
Carisoprodol withdrawal syndrome misdiagnosed as a psychotic disorder.
2008 Jul-Sep
Drug screening of hair by liquid chromatography-tandem mass spectrometry.
2008 Jun
[The Somadril Association in Norway].
2008 Jun 26
Urine drug testing of chronic pain patients: licit and illicit drug patterns.
2008 Oct
Carisoprodol-induced amnestic state and nocturnal blackouts.
2008 Oct
Carisoprodol should be taken off the market.
2008 Oct
Effects of naltrexone on pain sensitivity and mood in fibromyalgia: no evidence for endogenous opioid pathophysiology.
2009
Novel transcriptional profile in wrist muscles from cerebral palsy patients.
2009 Jul 14
A multi-drug intoxication fatality involving Xyrem (GHB).
2009 Mar
[Prescription shopping of addictive drugs in Norway].
2009 Mar 12
Prescription pattern of codeine for non-malignant pain: a pharmacoepidemiological study from the Norwegian Prescription Database.
2009 May
Carisoprodol-mediated modulation of GABAA receptors: in vitro and in vivo studies.
2009 May
A pilot study evaluating use of a computer-assisted neurorehabilitation platform for upper-extremity stroke assessment.
2009 May 28
Fibromyalgia and myofascial pain syndrome-a dilemma.
2009 Oct
Introduction of low dose transdermal buprenorphine -- did it influence use of potentially addictive drugs in chronic non-malignant pain patients?
2009 Oct
Regulation of intermittent oscillatory activity of pyramidal cell neurons by GABA inhibitory interneurons is impaired in schizophrenia: rationale for pharmacotherapeutic GABAergic interventions.
2010
Pharmacogenetics and forensic toxicology.
2010 Dec 15
Clinical perspective: monitoring sodium oxybate-treated narcolepsy patients for the development of sleep-disordered breathing.
2010 Feb
INCITE: A randomised trial comparing constraint induced movement therapy and bimanual training in children with congenital hemiplegia.
2010 Jan 12
Trace determination of pharmaceuticals and other wastewater-derived micropollutants by solid phase extraction and gas chromatography/mass spectrometry.
2010 Jan 22
Carisoprodol withdrawal after internet purchase.
2010 Jul
Pharmaceutical formulation facilities as sources of opioids and other pharmaceuticals to wastewater treatment plant effluents.
2010 Jul 1
The relation between neuromechanical parameters and Ashworth score in stroke patients.
2010 Jul 27
Adaptive robot training for the treatment of incoordination in Multiple Sclerosis.
2010 Jul 29
Pharmacologic management of chronic pain.
2010 Jun
Quantification of the effects of an alpha-2 adrenergic agonist on reflex properties in spinal cord injury using a system identification technique.
2010 Jun 23
Screening and quantitative determination of twelve acidic and neutral pharmaceuticals in whole blood by liquid-liquid extraction and liquid chromatography-tandem mass spectrometry.
2010 Sep
Patents

Sample Use Guides

250 mg to 350 mg three times a day and at bedtime
Route of Administration: Oral
In Vitro Use Guide
HEK293 cells were transiently transfected with human alpha1beta2 and alpha1beta2gamma2 receptors. Whole-cell patch clamp electrophysiology was used to assess carisoprodol-activated Cl- current. EC50 value for carisoprodol was 142 ± 13 uM.
Substance Class Chemical
Created
by admin
on Mon Mar 31 17:45:36 GMT 2025
Edited
by admin
on Mon Mar 31 17:45:36 GMT 2025
Record UNII
21925K482H
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
CARISOPRODOL CIV
USP-RS  
Preferred Name English
CARISOPRODOL
EP   HSDB   INN   JAN   MART.   MI   ORANGE BOOK   USP   VANDF   WHO-DD  
INN  
Official Name English
(±)-2-METHYL-2-PROPYL-1,3-PROPANEDIOL CARBAMATE ISOPROPYLCARBAMATE
Systematic Name English
CARISOPRODOL [HSDB]
Common Name English
CARISOPRODOL [USP MONOGRAPH]
Common Name English
NSC-172124
Code English
CARISOPRODOL [MI]
Common Name English
CARISOPRODOL [EP IMPURITY]
Common Name English
CARISOPRODOL [JAN]
Common Name English
carisoprodol [INN]
Common Name English
SOMA
Brand Name English
Carisoprodol [WHO-DD]
Common Name English
RELA
Brand Name English
SOMA COMPOUND COMPONENT CARISOPRODOL
Common Name English
CARISOPRODOL [VANDF]
Common Name English
CARISOPRODOL [ORANGE BOOK]
Common Name English
CARISOPRODOL CIV [USP-RS]
Common Name English
CARISOPRODOL COMPOUND COMPONENT CARISOPRODOL
Common Name English
CARISOPRODOL [MART.]
Common Name English
Classification Tree Code System Code
NDF-RT N0000175737
Created by admin on Mon Mar 31 17:45:36 GMT 2025 , Edited by admin on Mon Mar 31 17:45:36 GMT 2025
LIVERTOX NBK548829
Created by admin on Mon Mar 31 17:45:36 GMT 2025 , Edited by admin on Mon Mar 31 17:45:36 GMT 2025
WHO-ATC M03BA72
Created by admin on Mon Mar 31 17:45:36 GMT 2025 , Edited by admin on Mon Mar 31 17:45:36 GMT 2025
WHO-VATC QM03BA72
Created by admin on Mon Mar 31 17:45:36 GMT 2025 , Edited by admin on Mon Mar 31 17:45:36 GMT 2025
WHO-VATC QM03BA52
Created by admin on Mon Mar 31 17:45:36 GMT 2025 , Edited by admin on Mon Mar 31 17:45:36 GMT 2025
WHO-ATC M03BA02
Created by admin on Mon Mar 31 17:45:36 GMT 2025 , Edited by admin on Mon Mar 31 17:45:36 GMT 2025
NCI_THESAURUS C29696
Created by admin on Mon Mar 31 17:45:36 GMT 2025 , Edited by admin on Mon Mar 31 17:45:36 GMT 2025
WHO-VATC QM03BA02
Created by admin on Mon Mar 31 17:45:36 GMT 2025 , Edited by admin on Mon Mar 31 17:45:36 GMT 2025
DEA NO. 8192
Created by admin on Mon Mar 31 17:45:36 GMT 2025 , Edited by admin on Mon Mar 31 17:45:36 GMT 2025
WHO-ATC M03BA52
Created by admin on Mon Mar 31 17:45:36 GMT 2025 , Edited by admin on Mon Mar 31 17:45:36 GMT 2025
NDF-RT N0000175730
Created by admin on Mon Mar 31 17:45:36 GMT 2025 , Edited by admin on Mon Mar 31 17:45:36 GMT 2025
Code System Code Type Description
NCI_THESAURUS
C28904
Created by admin on Mon Mar 31 17:45:36 GMT 2025 , Edited by admin on Mon Mar 31 17:45:36 GMT 2025
PRIMARY
MESH
D002328
Created by admin on Mon Mar 31 17:45:36 GMT 2025 , Edited by admin on Mon Mar 31 17:45:36 GMT 2025
PRIMARY
SMS_ID
100000084595
Created by admin on Mon Mar 31 17:45:36 GMT 2025 , Edited by admin on Mon Mar 31 17:45:36 GMT 2025
PRIMARY
RS_ITEM_NUM
1096600
Created by admin on Mon Mar 31 17:45:36 GMT 2025 , Edited by admin on Mon Mar 31 17:45:36 GMT 2025
PRIMARY
WIKIPEDIA
CARISOPRODOL
Created by admin on Mon Mar 31 17:45:36 GMT 2025 , Edited by admin on Mon Mar 31 17:45:36 GMT 2025
PRIMARY
LACTMED
Carisoprodol
Created by admin on Mon Mar 31 17:45:36 GMT 2025 , Edited by admin on Mon Mar 31 17:45:36 GMT 2025
PRIMARY
FDA UNII
21925K482H
Created by admin on Mon Mar 31 17:45:36 GMT 2025 , Edited by admin on Mon Mar 31 17:45:36 GMT 2025
PRIMARY
DAILYMED
21925K482H
Created by admin on Mon Mar 31 17:45:36 GMT 2025 , Edited by admin on Mon Mar 31 17:45:36 GMT 2025
PRIMARY
CHEBI
3419
Created by admin on Mon Mar 31 17:45:36 GMT 2025 , Edited by admin on Mon Mar 31 17:45:36 GMT 2025
PRIMARY
IUPHAR
7610
Created by admin on Mon Mar 31 17:45:36 GMT 2025 , Edited by admin on Mon Mar 31 17:45:36 GMT 2025
PRIMARY
HSDB
3021
Created by admin on Mon Mar 31 17:45:36 GMT 2025 , Edited by admin on Mon Mar 31 17:45:36 GMT 2025
PRIMARY
DRUG BANK
DB00395
Created by admin on Mon Mar 31 17:45:36 GMT 2025 , Edited by admin on Mon Mar 31 17:45:36 GMT 2025
PRIMARY
EPA CompTox
DTXSID8024733
Created by admin on Mon Mar 31 17:45:36 GMT 2025 , Edited by admin on Mon Mar 31 17:45:36 GMT 2025
PRIMARY
PUBCHEM
2576
Created by admin on Mon Mar 31 17:45:36 GMT 2025 , Edited by admin on Mon Mar 31 17:45:36 GMT 2025
PRIMARY
NSC
172124
Created by admin on Mon Mar 31 17:45:36 GMT 2025 , Edited by admin on Mon Mar 31 17:45:36 GMT 2025
PRIMARY
CAS
78-44-4
Created by admin on Mon Mar 31 17:45:36 GMT 2025 , Edited by admin on Mon Mar 31 17:45:36 GMT 2025
PRIMARY
DRUG CENTRAL
509
Created by admin on Mon Mar 31 17:45:36 GMT 2025 , Edited by admin on Mon Mar 31 17:45:36 GMT 2025
PRIMARY
EVMPD
SUB06631MIG
Created by admin on Mon Mar 31 17:45:36 GMT 2025 , Edited by admin on Mon Mar 31 17:45:36 GMT 2025
PRIMARY
ECHA (EC/EINECS)
201-118-7
Created by admin on Mon Mar 31 17:45:36 GMT 2025 , Edited by admin on Mon Mar 31 17:45:36 GMT 2025
PRIMARY
MERCK INDEX
m3112
Created by admin on Mon Mar 31 17:45:36 GMT 2025 , Edited by admin on Mon Mar 31 17:45:36 GMT 2025
PRIMARY Merck Index
RXCUI
2101
Created by admin on Mon Mar 31 17:45:36 GMT 2025 , Edited by admin on Mon Mar 31 17:45:36 GMT 2025
PRIMARY RxNorm
INN
902
Created by admin on Mon Mar 31 17:45:36 GMT 2025 , Edited by admin on Mon Mar 31 17:45:36 GMT 2025
PRIMARY
ChEMBL
CHEMBL1233
Created by admin on Mon Mar 31 17:45:36 GMT 2025 , Edited by admin on Mon Mar 31 17:45:36 GMT 2025
PRIMARY
Related Record Type Details
BASIS OF STRENGTH->SUBSTANCE
ASSAY (TITRATION)
EP
ENANTIOMER -> RACEMATE
ENANTIOMER -> RACEMATE
BASIS OF STRENGTH->SUBSTANCE
ASSAY (HPLC)
USP
BINDER->LIGAND
BINDING
Related Record Type Details
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (TLC)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (TLC)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (TLC)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC